The addiction cycle is what happens when the reward circuit is repeatedly perturbed. It is not a metaphor — it is a measurable trajectory through which the brain reorganizes itself under the influence of a substance that floods the nucleus accumbens with dopamine.
First, tolerance. With repeated drug exposure, the postsynaptic side of the mesolimbic system down-regulates. Dopamine receptors internalize, baseline release falls, and the same dose of drug produces less subjective effect. The patient needs more to feel the same. This is true of cocaine, opioids, alcohol, and most stimulants.
Second, withdrawal. When the drug is removed, the system that had adapted to its presence now functions with a downregulated baseline. Endogenous reward is muted. Mood is low. Energy is gone. Sleep is broken. Anxiety is heightened. The specific withdrawal syndrome varies by drug — alcohol withdrawal can be life-threatening with seizures and autonomic instability; opioid withdrawal is intensely unpleasant but rarely fatal in adults; cocaine withdrawal is mostly subjective with crashing dysphoria and craving. All share the underlying physiology of a system suddenly missing the input it had adapted to.
Third, cue-induced craving. The amygdala and hippocampus have been quietly learning, throughout the period of use, which environmental cues predict the drug. The corner. The dealer's name. The pipe. The smell of alcohol. The particular bar. The Friday evening hour. These cues, on later exposure, produce anticipatory dopamine release in the nucleus accumbens — generating the felt experience of craving even in the absence of drug. This is the part of addiction that persists for years after the last use, and the part that drives relapse.
Fourth, loss of cortical control. The prefrontal cortex, which would normally evaluate and inhibit, becomes less able to override the limbic signal. Chronic substance use produces measurable thinning of cortical gray matter in regions important for decision-making and impulse control. The same drug that floods the accumbens also weakens the executive office.
The medications that work in addiction interrupt this cycle at different points. Buprenorphine, a partial mu-opioid agonist, occupies opioid receptors enough to dampen craving and withdrawal without producing the euphoric surge that drives the cycle. Naltrexone blocks opioid and reward signaling entirely. Acamprosate may stabilize glutamate signaling that goes haywire in alcohol withdrawal. Varenicline partially agonizes nicotinic receptors. Each medication targets a different node of the cycle.
Hold the cycle. Tolerance, withdrawal, cue-induced craving, weakened cortex. Each clinical phenomenon in addiction maps to one of these physiologic changes. The framing matters: addiction is a learned reorganization of reward circuitry, not a moral failure. The treatments work because they target that reorganization.